Usability of a novel disposable autoinjector device for ixekizumab: results from a qualitative study and an open-label clinical trial, including patient-reported experience

BACKGROUND: Most biologic therapies for psoriasis are delivered via subcutaneous injection. Ixekizumab, an anti-interleukin 17A monoclonal antibody approved for patients with moderate-to-severe plaque psoriasis, is delivered subcutaneously via prefilled syringe or autoinjector. Here we report the re...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Med Devices (Auckl)
Main Authors: Callis Duffin, Kristina, Bukhalo, Michael, Bobonich, Margaret A, Shrom, David, Zhao, Fangyi, Kershner, James R, Gill, Anne, Pangallo, Beth, Shuler, Catherine L, Bagel, Jerry
Formato: Artigo
Idioma:Inglês
Publicado em: Dove Medical Press 2016
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5067052/
https://ncbi.nlm.nih.gov/pubmed/27785115
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/MDER.S113752
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados